See more : Jinan High-tech Development Co., Ltd. (600807.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Ayala Pharmaceuticals, Inc. (AYLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ayala Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Pop Mart International Group Limited (9992.HK) Income Statement Analysis – Financial Results
- JTC PLC (JTCPF) Income Statement Analysis – Financial Results
- High Peak Royalties Limited (HPR.AX) Income Statement Analysis – Financial Results
- Teesta Agro Industries Limited (TEEAI.BO) Income Statement Analysis – Financial Results
- Digitalbox plc (DBOX.L) Income Statement Analysis – Financial Results
Ayala Pharmaceuticals, Inc. (AYLA)
About Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 692.00K | 0.00 | 3.71M | 2.33M | 0.00 |
| Cost of Revenue | 602.00K | 3.51M | 3.71M | 1.29M | 0.00 |
| Gross Profit | 90.00K | -3.51M | 0.00 | 1.05M | 0.00 |
| Gross Profit Ratio | 13.01% | 0.00% | 0.00% | 44.94% | 0.00% |
| Research & Development | 27.85M | 29.94M | 22.41M | 14.42M | 5.74M |
| General & Administrative | 9.74M | 9.28M | 7.37M | 4.34M | 3.29M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.74M | 9.28M | 7.37M | 4.34M | 3.29M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.59M | 39.22M | 29.78M | 18.76M | 9.04M |
| Cost & Expenses | 38.20M | 42.72M | 33.49M | 20.05M | 9.04M |
| Interest Income | 0.00 | 0.00 | 56.00K | 225.00K | 448.00K |
| Interest Expense | -74.00K | -1.55M | 56.00K | 225.00K | 0.00 |
| Depreciation & Amortization | 162.00K | 168.00K | 182.00K | 150.00K | 49.00K |
| EBITDA | -37.50M | -40.86M | -29.48M | -17.11M | -8.54M |
| EBITDA Ratio | -5,419.51% | 0.00% | -795.12% | -733.12% | 0.00% |
| Operating Income | -37.50M | -41.03M | -29.78M | -17.71M | -9.04M |
| Operating Income Ratio | -5,419.51% | 0.00% | -803.05% | -758.83% | 0.00% |
| Total Other Income/Expenses | 74.00K | 3.25M | 56.00K | 225.00K | 448.00K |
| Income Before Tax | -37.43M | -39.48M | -29.72M | -17.49M | -8.59M |
| Income Before Tax Ratio | -5,408.82% | 0.00% | -801.54% | -749.19% | 0.00% |
| Income Tax Expense | 584.00K | -776.00K | 425.00K | 306.00K | 286.00K |
| Net Income | -38.01M | -38.70M | -30.15M | -17.79M | -8.87M |
| Net Income Ratio | -5,493.21% | 0.00% | -813.00% | -762.30% | 0.00% |
| EPS | -2.46 | -3.92 | -3.06 | -2.07 | -1.31 |
| EPS Diluted | -2.46 | -3.92 | -3.06 | -2.07 | -1.31 |
| Weighted Avg Shares Out | 15.45M | 9.86M | 9.86M | 8.58M | 6.77M |
| Weighted Avg Shares Out (Dil) | 15.45M | 9.86M | 9.86M | 8.58M | 6.77M |
Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
How Much Upside is Left in Ayala Pharmaceuticals, Inc. (AYLA)? Wall Street Analysts Think 116%
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Misses Revenue Estimates
Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference
Earnings Preview: Ayala Pharmaceuticals, Inc. (AYLA) Q3 Earnings Expected to Decline
Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Lags Revenue Estimates
Recap: Ayala Pharmaceuticals Q2 Earnings
Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Source: https://incomestatements.info
Category: Stock Reports